Anti-SNX7 Polyclonal Antibody for WB, ELISA - Q9UNH6

Core Product Specifications and Parameters

Biological Background: SNX7 Function and Localization

• SNX7 encodes sorting nexin-7, a member of the sorting nexin family characterized by a phox (PX) domain that facilitates phosphoinositide binding and membrane association.
• It is involved in the regulation of endocytosis and multiple stages of intracellular trafficking, particularly at the early endosome membrane.
• In conjunction with SNX4, SNX7 contributes to autophagosome assembly by controlling the trafficking and recycling of the phospholipid scramblase ATG9A. Related references: PMID:32513819
• SNX7 localizes predominantly to the early endosome membrane, consistent with its role in endosomal sorting and trafficking.
• The protein contains a lipid-binding PX domain, enabling direct interaction with endosomal phospholipids and facilitating membrane recruitment.
• Alternative splicing of the SNX7 gene produces multiple transcript variants, though the functional significance of distinct isoforms is not fully characterized.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a central region (aa 85-330) of human SNX7, which may recognize multiple isoforms; consider verifying isoform-specific reactivity in the target sample.
• For Western blot, a band around 45 kDa is expected; validate detection in positive controls such as human cell lines expressing SNX7 and in mouse/rat tissues given the reported cross-reactivity.
• ELISA performance has been demonstrated; optimization of coating antigen and antibody dilution may be needed depending on the assay format.
• Since SNX7 interacts with ATG9A and other trafficking proteins, co-immunoprecipitation experiments may be feasible; however, the antibody's suitability for IP should be empirically validated.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with comprehensive access to IVD raw materials, including validated antibodies for intracellular trafficking and autophagy targets like SNX7. We offer a full range of polyclonal and monoclonal antibodies, complementary antibody pairs, and bulk ancillary reagents to support assay development. Our sourcing capabilities extend to rare and emerging targets, enabling seamless progress from early-stage research to clinical application.